In search for novel antiseizure drugs (ASDs), the European FP7-funded PharmaSea project used zebrafish embryos and larvae as a drug discovery platform to screen marine natural products to identify promising antiseizure hits in vivo for further development. Within the framework of this project, 7 known hetero-spirocyclic γ-lactams, namely pseurotin A, pseurotin A2, pseurotin F1, 11-O-methylpseurotin A, pseurotin D, azaspirofuran A, and azaspirofuran B, were isolated from the bioactive marine fungus Aspergillus fumigatus, and their antiseizure activity was evaluated in the larval zebrafish pentylenetetrazole (PTZ) seizure model. Pseurotin A2 and azaspirofuran A were identified as antiseizure hits, while their close chemical analogues were inactive. Besides, electrophysiological analysis from the zebrafish midbrain demonstrated that pseurotin A2 and azaspirofuran A also ameliorate PTZ-induced epileptiform discharges. Next, to determine whether these findings translate to mammalians, both compounds were analyzed in the mouse 6-Hz (44 mA) psychomotor seizure model. They lowered the seizure duration dose-dependently, thereby confirming their antiseizure properties and suggesting activity against drug-resistant seizures. Finally, in a thorough ADMET assessment, pseurotin A2 and azaspirofuran A were found to be drug-like. Based on the prominent antiseizure activity in both species and the drug-likeness, we propose pseurotin A2 and azaspirofuran A as lead compounds that are worth further investigation for the treatment of epileptic seizures. This study not only provides the first evidence of antiseizure activity of pseurotins and azaspirofurans, but also demonstrates the value of the zebrafish model in (marine) natural product drug discovery in general, and for ASD discovery in particular.
INTRODUCTION
Epilepsy is one of the most common neurological conditions, affecting more than 70 million people of all ages with no geographical, social, or racial boundaries. [1] [2] [3] It is a disease of the brain that is characterized by spontaneous recurrent unprovoked seizures. 4 Despite an exponential growth of marketed antiseizure drugs (ASDs) over the past 25 years, seizures remain uncontrolled in one third of the patients due to drug resistance. 5, 6 As uncontrolled epilepsy is associated with increased physical and physiological comorbidities and increased risk of sudden unexplained death, there is a substantial burden on the patients, their caretakers and society. 6 Hence, more efficacious ASDs that can treat patients with drug-resistant seizures are sorely needed. 7 The EU PharmaSea project, funded by the Seventh Framework Programme (FP7), is an SMEacademia-driven project of 24 partners that was initiated in 2012 to discover novel antibiotic,
anti-inflammatory and neuroactive compounds from marine microorganisms isolated from some of the deepest, coldest, and hottest places on the planet. 8 Neuroactive drug discovery focused on the identification of compounds with the potential to treat epilepsy. To the best of our knowledge, we have been the first to perform systematic large-scale screening of marinederived natural products for antiseizure drug candidates. Marine species offer an attractive source for drug discovery because they produce potent, selective, and structurally novel bioactive secondary metabolites to defend themselves, to locate mates, and to out-compete competitors for limited resources. [8] [9] [10] Many of these do not have a terrestrial analogue and are thus unique in terms of chemical structure and bioactivity. 8, 9 Among them are marine-derived natural products that can alter mammalian neurological activity. Classical examples are tetrodotoxins, saxitoxins, kainic and domoic acids, cone snail venom peptides, and sea anemone toxins. 10 Nevertheless, marine natural products are highly underutilized in drug discovery. 11 A main reason is the lack of systematic analysis in high-content bioassays given the often limited quantities of marine natural products available for screening purposes.
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The zebrafish model is suitable for large-scale screening and captures the complexity of a whole body organism, including the central nervous system. As a vertebrate, zebrafish are highly similar to humans due to a high genetic, physiological and pharmacological conservation. [12] [13] [14] Moreover, given the small size of embryos and larvae, they fit in wells of microtiter plates and hence are suitable for medium to high-throughput testing. 13, 14 Given the low volumes used in 96-and 384-well plates, zebrafish larvae only require small amounts of sample in the low microgram range when added to their swimming water and even less when administered by injection. This property is of particular interest for marine natural product drug discovery, where material is often scarce. 11 Within the PharmaSea project, marine samples were screened in 96-well plate format using only 10 µg per well per screening round. From the established larval zebrafish seizure and epilepsy models 15 , the larval zebrafish pentylenetetrazole (PTZ) seizure model was chosen for drug discovery because: 1) the model has been extensively characterized in terms of behavioral and non-behavioral seizure markers 16, 17 , 2) it has been pharmacologically characterized with ASDs on the market [16] [17] [18] , 3) results translate well to rodent models 17, 19, 20 , and 4) the behavioral assay is suitable for high-throughput screeningseizures can easily and rapidly be induced by a single administration of the convulsant drug to the larva's aqueous environment 16 and can be quantified by video recording [16] [17] [18] .
Within the framework of the PharmaSea project, 5 pseurotins (pseurotin A, pseurotin A2, pseurotin F1, 11-O-methylpseurotin A, and pseurotin D) and 2 azaspirofurans (azaspirofuran A and B) were isolated from extracts of the bioactive marine fungus Aspergillus fumigatus, which was collected from a Red Sea sediment in Hurghada, Egypt. Interestingly, these compounds did not demonstrate antibacterial activity or cytotoxicity in contrast to other constituents from the crude extract 21 and were readily available for further biological evaluation. Pseurotins are a family of fungal secondary metabolites that have not been well studied so far, except for pseurotin A that was found to exhibit a range of bioactivities at moderate to high test concentrations (up to 50 µg/mL). [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Azaspirofurans are chemically very similar to pseurotins, but feature an ethyl furan ring instead of a vicinal diol ( Figure 1 ). Little is known about the bioactivities of azaspirofurans as they were identified only recently. 32 So far, azaspirofuran A was observed to specifically inhibit the proliferation of the A459 cancer cell line. 32, 33 All compounds were investigated for antiseizure activity in the larval zebrafish PTZ seizure model. Interestingly, despite close structural similarities, only pseurotin A2 and azaspirofuran A ameliorated PTZ-induced seizures, suggesting a highly specific interaction. Besides, electrophysiological analysis from the zebrafish midbrain demonstrated that pseurotin A2 and azaspirofuran A also significantly lowered PTZ-induced epileptiform discharges. Next, the antiseizure activity of pseurotin A2 and azaspirofuran A was demonstrated in the mouse 6-Hz (44 mA) psychomotor seizure model. These results not only confirmed the translation of findings from zebrafish larvae to mice but also suggested that pseurotin A2 and azaspirofuran A are effective against drug-resistant focal seizures. Finally, ADMET profiling showed that both compounds are drug-like. Based on the prominent antiseizure activity and the promising ADMET characteristics, we propose pseurotin A2 and azaspirofuran A as lead compounds that are worth further investigation for the treatment of seizures.
RESULTS AND DISCUSSION
Isolation and structural elucidation of compounds from the bioactive marine fungus
Aspergillus fumigatus
The marine fungal isolate MR2012 used in this study was isolated from a Red Sea sediment in Hurghada, Egypt and taxonomically identified on a molecular basis as Aspergillus fumigatus 21 .
Compounds Figure 1 ). Their structures were confirmed by HRESIMS analysis and by comparing the 1D and 2D NMR spectra and optical rotation with literature data as indicated (see supporting information for their 1D NMR data).
Azaspirofuran A and pseurotin A2 ameliorate seizures in the zebrafish PTZ seizure model
To investigate whether the isolated compounds display antiseizure activity, they were tested in the larval zebrafish PTZ seizure model both after a short (2 hours (h)) and long (18 h ) incubation time at their maximum tolerated concentration (MTC) ( Table 1 ). The MTC was defined as the highest concentration at which no larvae died nor showed signs of toxicity or locomotor impairment in comparison to vehicle (VHC)-treated control larvae. In case no MTC was reached, 100 µg/mL was used as the test concentration. In line with studies previously reported 16, 17 , addition of the GABAA-receptor antagonist PTZ to the swimming water of 7-days post-fertilization (dpf) zebrafish larvae strongly elevated larval locomotion (p ≤ 0.001) ( Figure 3C ) as during the 5-min time intervals (p ≤ 0.001, Figure 3D ).
Azaspirofuran A and pseurotin A2 ameliorate epileptiform brain activity in the zebrafish
PTZ seizure model
To determine whether azaspirofuran A and pseurotin A2 can ameliorate the PTZ-induced hyperexcitable state of the brain that is characterized by epileptiform discharges 39 , local field potential (LFP) recordings 40 were non-invasively measured from the midbrain (optic tectum) of zebrafish larvae. To that end larvae were treated with either VHC or test compound (MTC and optimal incubation time was used) followed by a 15 min during exposure to PTZ or VHC prior to the electrophysiology measurements ( Figure The identification and validation of these novel antiseizure hits thereby demonstrate the effectiveness of using the larval zebrafish model for ASD discovery. Besides, this study provides another example of the translation of results from zebrafish to rodent seizure models.
Little is known about the molecular mechanisms underlying the bioactivities of azaspirofuran A and pseurotin A2 in general. Therefore, it is difficult to speculate on the antiseizure drug targets that could be involved. Of note, pseurotin A2 was reported to exert anti-inflammatory activity, a promising mode of action that has been proposed for the development of innovative ASDs and AEDs as neuroinflammation is involved in the origin of seizures and epilepsy. 29, 48, 49 In addition, pseurotin A is known to induce neuronal cell differentiation. 22 This long-term effect is unlikely to be involved in the antiseizure actions of azaspirofuran A and pseurotin A2 in this study because of the short-term exposure (2 and 18 h of exposure, respectively), but it is of particular interest for AED development. Further research is needed to unravel the molecular mechanisms of azaspirofuran A and pseurotin A2 that are responsible for their antiseizure activity against PTZ-induced seizures in zebrafish and focal seizures in mice.
ADMET profiling of azaspirofuran A and pseurotin A2
Finally, to define the drug-likeness of the antiseizure lead compounds, the ADMET profiles of azaspirofuran A and pseurotin A2 were elucidated using standard in vitro assays. The ADMET results are summarized in 
CONCLUSIONS
In this study, 7 known hetero-spirocyclic γ-lactams were isolated from the marine sediment- with a Waters Sunfire C18 column (5 μm, 100 Å, 10 mm × 250 mm), connected to a binary pump, and monitored using a photodiode array detector.
Microbial strain
The marine fungal isolate MR2012 used in this study was isolated from a Red Sea sediment in Hurghada, Egypt in September 2011, and taxonomically identified on a molecular basis as 21 .
Aspergillus fumigatus

Microbial fermentation, extraction, and isolation
The fungal isolate MR2012 initially cultured on a solid medium composed of (g/L) glucose 10, 
Compound preparation
For experiments with zebrafish larvae, dry samples were dissolved in 100 % dimethyl sulfoxide 
Compound LogP prediction
LogP (ACD/LogP) values were obtained from ChemSpider and predicted by means of the ACD/Labs Percepta Platform (PhysChem Module) based on the compound structure 50 .
Experimental animals
All animal experiments carried out were approved by the Ethics Committee of the University 
Mice
Male NMRI mice (weight 18-20 g) were acquired from Charles River Laboratories and housed in poly-acrylic cages under a 14/10-h light/dark cycle at 21 °C. The animals were fed a pellet diet and water ad libitum, and were allowed to acclimate for one week before experimental procedures were conducted. Prior to the experiment, mice were isolated in a poly-acrylic cage with a pellet diet and water ad libitum for habituation overnight in the experimental room, to minimize stress.
Zebrafish pentylenetetrazole seizure model
Toxicity evaluation
Maximum tolerated concentration (MTC) was determined prior to further experiments and used
as the highest test concentration. Experimental procedure was described before 51 . In brief, the MTC was investigated by exposing 12 larvae of 6 dpf to a range of concentrations in a 100 µL volume during 18 h. The following parameters were investigated after 2 and 18 h of exposure:
touch response, morphology, posture, edema, signs of necrosis, swim bladder, and heartbeat.
MTC was defined as the highest concentration at which no larvae died nor showed signs of toxicity or locomotor impairment in comparison to VHC-treated control larvae. In case no MTC was reached, 100 µg/mL was used as the highest test concentration.
Behavioral analysis
Experimental procedure was described before 17, 20 . In brief, a single 7-dpf larva (in case of 2 h incubation) or 6-dpf larva (in case of 18 h incubation) was placed in each well of a 96-well plate and treated with either VHC (1 % DMSO) or compound in a 100 µL volume. Larvae were incubated in dark for 2 or 18 h at 28 °C, whereafter 100 µL of either VHC (embryo medium) 
Electrophysiology
Experimental procedure was described before [51] [52] [53] . In brief, non-invasive LFP recordings were measured from the midbrain of 7-dpf zebrafish larvae pre-incubated with VHC only, PTZ only, 
ADMET profiling
Cell viability and MTT assays
Experimental procedure was described before 54 . Next, the medium was replaced with medium complemented with test compounds at different concentrations. After another 24 h incubation, the medium was replaced by 100 µL of a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/mL in PBS and diluted at 0.5 mg/mL in MEM without phenol red). The plates were gently shaken and incubated for 3 h at 37 ºC in a 5 % CO2 incubator. The supernatant was removed and 100 µL of 100 % DMSO was added. The plates were gently shaken to solubilize the formed formazan. The absorbance was measured using a multireader (Victor2 (Wallac)) at a wavelength of 570 nm.
Cardiotoxicity
Fluorescence-based assays were performed using HEK293 cell lines that stably express the Nav1.5-channel, Cav1.2-channel, or hERG K + -channel, using FMP Red Dye (Molecular Devices), calcium-sensitive fluorescent dye Fluo-4 (Invitrogen) and FluxOR™ reagent (Invitrogen), respectively, and a FLIPR Tetra High-Throughput Cellular Screening System (Molecular Devices), according to manufacturer's protocols (Molecular Devices).
Tetrodotoxin, israpidine and nicarpidine, and astemizole and haloperidol were used as standard sodium channel, calcium channel, and hERG channel blockers. Data were analyzed using Genedata Screener.
CYP450 enzyme inhibition assay
Experimental procedure was described before 55 ppb 4′-hydroxydiclofenac-13 C6, 60 ppb levallorphan).
Metabolic stability assay
The assay was performed with a mixture of test compounds (1 µM), NADPH (4 mM) and HLM
(1 mg/mL) incubated at 37 °C. Reactions were quenched at 0, 15, 30, 45, 60, and 90 min, using an equal volume of ACN and then diluted 1:1 with water prior to analysis by LC-MS/MS.
The analysis was performed using an Agilent Series 1290 LC system (Agilent Technologies, Santa Clara, CA, USA) using a Supelco Discovery HS C18 (2.1×50 mm) 3 μm column that was held at 30 °C. Solvent A contained water with 0.1 % formic acid and solvent B contained ACN with 0.1 % formic acid, and the flow rate was set at 400 μL/min. The gradient elution was performed as follows: 0-0.5 min 0 % eluent B; 0.5-7 min 100 % eluent B; 7-9 min 100 % eluent B; 9-9.2 min 0 % eluent B; and 9.2-10.5 min 0 % eluent B. An API 4000 mass spectrometer in positive ESI mode (AB SCIEX, Concord, ON, Canada) was used with a generic method for data acquisition on all compounds. Data processing was performed using MultiQuant Software (AB SCIEX, Concord, ON, Canada) to process the data. Peak areas were used to plot the Ln % remaining relative to time (t) = 0. The slope of the natural log of the percent remaining versus time was calculated to determine the first-order rate constant (k) and the half-life (t1/2) of the test compounds according to the following equation: t1/2 = 0.693/k (min)
Kinetic solubility assay
Experimental procedure was described before 56 . The kinetic solubility assay was conducted in 96-well, flat-bottom, transparent polystyrene plates (Costar 9018, Corning, Tewksbury MA).
Six two-fold serial dilutions of an initial 10 mM test compound solution were prepared in DMSO. After a 2-h incubation period (to avoid missing slow precipitation) absorbance was measured at 620 nm by an EnVision multilabel plate reader. The kinetic solubility was estimated from the concentration of test compound that produced an increase in absorbance above the background levels (i.e., 1 % DMSO in buffer).
Plasma protein binding assay
Experimental procedure was described before 57 . 
Parallel artificial membrane permeability assay (PAMPA)
The Gentest Pre-coated PAMPA Plate System (Corning) was used to perform the permeability assays. The 96-well filter plate, pre-coated with lipids, was used as the permeation acceptor and a matching 96-well receiver plate was used as the permeation donor. 
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